Welcome to BioSeeker Group!

Triple Analysis: Colorectal Cancer, Prostate Cancer and Apoptosis

Additional Information

Published Date Sep 12, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4166
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Colorectal Cancer, Prostate Cancer and Apoptosis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Prostate Cancer and by the mechanism/target/effect of Apoptosis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Prostate Cancer and Apoptosis.

    To find out more about Triple Analysis: Colorectal Cancer, Prostate Cancer and Apoptosis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Prostate Cancer and Apoptosis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Prostate Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part III: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
10 Disclaimer 1040
11 Drug Index 1041
12 Company Index 1050
Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part II: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

Part III: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

This Report Includes the Following Companies:
Abbott
Access
Active Biotech
Adherex
Advanced Life Sciences
Advantagene
AEgera
AEterna Zentaris
Affimed Therapeutics
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
Alnylam
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambrilia Biopharma
American Gene Technology International
Amgen
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
AndroBioSys
Antisense Pharma
Antisense Therapeutics
Antisoma
Aphios
Apogenix
ApopLogic Pharmaceuticals
Apotex
Aprea
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Avila Therapeutics
Basilea Pharmaceutica
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Betapharma
BioAlliance Pharma
BioAxone
Biocad
Biocompatibles
Bioenvision
Biogen Idec
BioInvent
BioLineRx
BioMarin
Biomas
BioNetWorks
Bionovo
BioNumerik
BioSante
Biostar
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Camurus
Can-Fite BioPharma
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Cel-Sci
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemGenex Pharmaceuticals
ChemoCentryx
Chemokine Therapeutics
Chlorogen
Choongwae
Chroma Therapeutics
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
Colby
CombinatoRx
Coronado Biosciences
Cosmo Bioscience
Cosmo Pharmaceuticals
Critical Outcome Technologies
CuraGen
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
Dongkook Pharm
Dynavax Technologies
ECI
EGEN Inc
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Endocyte
Enkam Pharmaceuticals
Ensemble Discovery
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Erimos
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
FasTrack Pharmaceuticals
Ferring
Formula Pharmaceuticals
Galena Biopharma
Gemin X Pharmaceuticals
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
GenVec
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
Glycotope
Got-a-Gene
GP Pharm
GPC Biotech
Gradalis
Green Cross
GTx
Harbor BioSciences
Heidelberg Pharma
Hoffmann-La Roche
Human Genome Sciences
Idera Pharmaceuticals
IGF Oncology
IkerChem
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Inovio
Insmed
Insys Therapeutics
Intradigm
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
Kalypsys
Karo Bio
Keryx Biopharmaceuticals
Kiadis
Kinex
Kyowa Hakko Kirin
Labopharm
Leo
Ligand
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Medivation
Menarini
Merck & Co
Merck KGaA
Merrimack
Merrion Pharmaceuticals
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mojave Therapeutics
Molecular Insight
MolMed
Mologen
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NicOx
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
Novelix
Novogen
Nycomed Pharma
Oasmia
OncoGenex Pharmaceuticals
OncoMed
Onconova
Oncothyreon
Oncovir
Oncozyme Pharma
Onyvax
Orca Therapeutics
Orchestra Therapeutics
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Pantarhei Bioscience
Patrys
Pepscan Therapeutics
Pfizer
Pharmaclon
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
Pierre Fabre
Plexxikon
POZEN
Pro-Pharmaceuticals
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
ProStrakan
Protherics
Q Chip
QLT
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Rexahn
Rigel
Rosetta Genomics
Salzburg Therapeutics
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sapphire Therapeutics
Sareum
SBI Biotech
SBIO
Seattle Genetics
SeleXel
Semafore Pharmaceuticals
Senesco Technologies
Serometrix
SGX Pharmaceuticals
Shire
Siena Biotech
Sigma-Tau
Simcere Pharmaceuticals
Soligenix
Sophiris Bio
Spirogen
SRI International
SuperGen
Supratek Pharma
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targepeutics
Tau Therapeutics
Taxolog
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
The Genetics Company
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tokai Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
Twinstrand Therapeutics
UMN Pharma
Unigene
United Biomedical
ValiRx
Vaxon Biotech
VBL Therapeutics
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viragen
Viralytics
ViroTarg
VM Discovery
Wyeth
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
abarelix
abiraterone acetate
adecatumumab
aderbasib
AEG-35156
AEZS-108
afatinib
aflibercept
ALT-801
alvocidib
AME-133
amonafide dihydrochloride
amonafide malate
Angiozyme
APC-100
APG-101
APR-246
ARC-100
ARQ-197
AS-101
AS-1411
atrasentan
AVX-701
bafetinib
bardoxolone methyl
belinostat
bevacizumab
BIBF-1120
bicalutamide
BMS-777607
BMS-936558
bortezomib
bosutinib
BP-GMAX-CD1
brivanib alaninate
buserelin
BZL-101
Cabozantinib
canfosfamide hydrochloride
capecitabine
carlumab
catumaxomab
cediranib
celecoxib
cenersen
cetuximab
cintredekin besudotox
cixutumumab
conatumumab
crolibulin
custirsen
danusertib
dasatinib
DCVax-prostate
degarelix
denosumab
deslorelin
DI-17E6
dinaciclib
docetaxel
dovitinib lactate
doxercalciferol
doxifluridine
doxorubicin
dulanermin
dutasteride
E-75
entinostat
enzastaurin hydrochloride
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
figitumumab
flutamide
fosbretabulin tromethamine
fulvestrant
gataparsen
GDC-0980
gefitinib
goserelin
GT-111
GTx-758
GVAX
GVX-3322
GX-301
HE-3235
histrelin
ibritumomab tiuxetan
idronoxil
imatinib mesilate
imetelstat
inecalcitol
INSM-18
interferon gamma
interleukins
intetumumab
ipilimumab
irinotecan bead
irinotecan hydrochloride
irosustat
ispinesib mesylate
kahalalide F
KX2-391
lapatinib ditosylate
lestaurtinib
leucine-doxorubicin
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
LIP-131I
LipoVIL12
litronesib
lonaprisan
LOR-2040
LOR-2501
lumiliximab
LY-2275796
mapatumumab
MCS-110
MDV-3100
MGN-1703
MKC-1
MLN-8237
mocetinostat
motexafin gadolinium
Nab-docetaxel
nadroparin
navitoclax
nilutamide
nimotuzumab
noscapine
obinutuzumab
oblimersen sodium
OGX-427
olaparib
olaratumab
ON-01910
Oncohist
orteronel
ozarelix
paclitaxel
paclitaxel polyglumex
panitumumab
panobinostat
PAT-SC1
PBI-1402
PCI-24781
perifosine
pertuzumab
plitidepsin
PLX-3397
ProstAtak
PROSTVAC
PRX-302
PX-12
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
raltitrexed
ramucirumab
regorafenib
retaspimycin
ridaforolimus
rilotumumab
romidepsin
ruxolitinib
sagopilone
sargramostim
SB-939
seliciclib
siltuximab
sipuleucel-T
sorafenib tosylate
SPC-2996
ß-lapachone
SU-6668
TAK-448
tandutinib
tasquinimod
tegafur + uracil
tegafur + uracil + leucovorin
temsirolimus
Tenarad
terameprocol
tigapotide triflutate
tigatuzumab
tipifarnib
TL-32711
TOK-001
toremifene citrate
TRC-105
tremelimumab
triciribine phosphate
trilostane
triptorelin
TroVax
TRU-016
TS-1
tucotuzumab celmoleukin
vandetanib
volasertib
vosaroxin
XL-147
XL-647
YM-155
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Prostate Cancer and Apoptosis.
    To find out more about Triple Analysis: Colorectal Cancer, Prostate Cancer and Apoptosis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Prostate Cancer and Apoptosis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Lymphoma, Pancreatic Cancer and Prostate Cancer. Learn More


Triple Analysis: Pancreatic Cancer, Apoptosis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Antibodies in Oncology: Analytical Tool
This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of antibodies in oncology. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More


Peptides in Oncology: Drug Pathway Analyzer
There are today at least 256 peptide drugs known to affect more than 222 specific intracellular signaling pathways for the treatment of more than 94 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 221 drug targets that are included in this drug-pathway analyzing tool. No less than 218 of these have been recorded with mutations and 29 drug targets have mutations which have been causally implicated in cancer. Learn More